Scorpius Holdings Inc

Análisis de la acción Scorpius Holdings Inc (SCPX)

$0.068

-0.033 (-48.48%)Al cierre

Loading chart…
High
0.133
Open
0.129
VWAP
0.09
Vol
1.31M
Mkt Cap
Low
0.058
Amount
113.35K
EV/EBITDA, TTM
0.00

Scorpius Holdings, Inc., formerly NightHawk Biosciences, Inc., is an integrated contract development and manufacturing company. The Company is focused on advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. Its analytical services include development of a comprehensive range of analytical test methods to characterize complex biologics, including cell therapy-based products, protein therapeutics, vaccines and advanced therapies. Its Clinical Biomanufacturing includes cGMP Mammalian Cell Culture, and cGMP Microbial Fermentation. Its San Antonio facility is focused on the commercial-scale manufacturing of biodefense-focused molecules and biologics therapeutics. Its biomanufacturing services focus on accelerating product development timelines from pre-clinical evaluation to first-in-human studies.

Métricas de valoración

The current forward P/E ratio for Scorpius Holdings Inc (SCPX) is -0.05, compared to its 5-year average forward P/E of -1.93.

Forward P/E

Fair
5Y Average P/E
-1.93
Current P/E
-0.05
Sobrevalorada
0.46
Infravalorada
-4.31

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Forward P/S

Fair
5Y Average P/S
9.39
Current P/S
0.04
Sobrevalorada
29.08
Infravalorada
-10.29

Cronología de eventos

2026-07-09 (ET)

14:30:00

OpenAI Launches GPT-5.6 Model Series, Pricing Starts at $1

2026-07-02 (ET)

10:30:00

Trump Administration Will Not Renew USMCA

2025-12-11 (ET)

10:00:00

Tivic Health Acquires Scorpius Assets and Launches Velocity Bioworks

2025-05-05 (ET)

08:03:06

Scorpius Holdings announces cost optimization including 28% headcount reduction

2025-04-21 (ET)

16:02:51

NYSE American to commence delisting proceedings against Scorpius Holdings

Noticias

SCPX FAQ — answered by Alphio AI

Scorpius Holdings, Inc., formerly NightHawk Biosciences, Inc., is an integrated contract development and manufacturing company. The Company is focused on advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its facilities in San Antonio, Texas. Its analytical services include development of a comprehensive range of analytical test methods to characterize complex biologics, including cell therapy-based products, protein therapeutics, vaccines and advanced therapies. Its Clinical Biomanufacturing includes cGMP Mammalian Cell Culture, and cGMP Microbial Fermentation. Its San Antonio facility is focused on the commercial-scale manufacturing of biodefense-focused molecules and biologics therapeutics. Its biomanufacturing services focus on accelerating product development timelines from pre-clinical evaluation to first-in-human studies. It operates in the Healthcare sector.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis